Advances in drug therapy of gastroesophageal reflux disease

doi:10.3969/j.issn.1004-583X.2017.01.005

Clinical Focus

Previous Articles Next Articles

Advances in drug therapy of gastroesophageal reflux disease

Department of Gastroenterology， the Second Hospital of Hebei Medical University; Hebei Key Laboratory of
Gastroenterology; Hebei Institute of Gastroenterology， Shijiazhuang 050000，China

Online:2017-01-05 Published:2017-01-12
Contact: Corresponding author: Zhang Xiaolan， Email: xiaolanzh@126.com

Abstract

Abstract: The incidence of gastroesophageal reflux disease (GERD) increases year by year. The treatment includes drug therapy， endoscopy therapy and surgery. Proton pump inhibitor (PPI) has been regarded as the firstline therapy. However， partial patients showed poor efficacy to PPI in recent years. Longterm application of PPI is related with Clostridium difficile infection. Morever， the combination with antiplatelet drugs may resultin cardiovascular events. This article reviews the advance of drug therapy of GERD， expecting to provide evidence for clinical practice.

Key words: gastroesophageal reflux, drug therapy, proton pump inhibitor; , antacids, prokinetic agents

Han Fei， Zhang Xiaolan. Advances in drug therapy of gastroesophageal reflux disease[J]. Clinical Focus, doi: 10.3969/j.issn.1004-583X.2017.01.005.

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2017.01.005

https://huicui.hebmu.edu.cn/EN/Y2017/V32/I1/17

[1]	Luo Fanglin, Guan Suying, Wu Guoxiang. Clinical effect of sacubitril-valsartan combined with activin on acute left heart failure [J]. Clinical Focus, 2021, 36(9): 782-785.
[2]	Gao Xinglian, Tong Zongwu, Yang Chongmeng, Zhao Yanhong, Lu Yongxin, Ding Rong. A case of AL type amyloidosis nephropathy treated with sequential chemotherapy [J]. Clinical Focus, 2021, 36(3): 266-269.
[3]	Lu Haoyang, Lu Jiazhong, Han Mingfeng, Lvh Xincai, Zhang Biao, Rong Chengzhen, Jia Leilei, Pan Qiangqiang, Ma Leilei, Zhao Ren. Observations on clinical treatment of COVID-19 complicated with cardiovascular disease [J]. Clinical Focus, 2021, 36(3): 203-207.
[4]	Zhang Jiahong, Zhou Shuhong, Zhou Jing, Wang Huijuan. Clinical observation of thalidomide in treatment of connective tissue disease associated interstitial lung disease [J]. Clinical Focus, 2019, 34(7): 622-625.
[5]	Bei Liye1, 2, Shi Yuye1, 2, Wang Chunling1, 2. Lenalidomide in treatment of relapsed/refractory nonHodgkin's Bcell lymphoma [J]. Clinical Focus, 2019, 34(6): 508-513.
[6]	Ted Wu1， Liu Shan2， Xu Zhangrong3. Update in diabetes medications [J]. Clinical Focus, 2017, 32(8): 654-657.
[7]	Han Ying. Current management of noncardiac chest pain [J]. Clinical Focus, 2017, 32(1): 50-53.
[8]	Ding Yu， Yan Xiue. Research progress of relationship between eosinophilic esophagitis and gastroesophageal reflux disease#br# [J]. Clinical Focus, 2017, 32(1): 42-45.
[9]	Su Shaohui. Psychosomatic factors and treatment of gastroesophageal reflux disease#br# [J]. Clinical Focus, 2017, 32(1): 37-41.
[10]	Liu Gaifang. Helicobacter pylori infection and gastroesophageal reflux disease [J]. Clinical Focus, 2017, 32(1): 33-36.
[11]	Wu Jimin. Discussion of relevant issues about surgical treatment on gastroesophageal reflux disease#br# [J]. Clinical Focus, 2017, 32(1): 28-32.
[12]	Jiang Wenjun， Zhou Liya. Endoscopic therapy of gastroesophageal reflux disease [J]. Clinical Focus, 2017, 32(1): 22-27,32.
[13]	Niu Weiwei， Yin Fengrong. Advances in diagnosis of gastroesophageal reflux disease [J]. Clinical Focus, 2017, 32(1): 13-16,21.
[14]	Bai Yan1， Bai Wenyuan2. Advances in identification and treatment of refractory gastroesophageal reflux disease#br# [J]. Clinical Focus, 2017, 32(1): 9-12.
[15]	Han Ying. Biomarkers of gastroesophageal reflux disease [J]. Clinical Focus, 2017, 32(1): 5-8,12.

Advances in drug therapy of gastroesophageal reflux disease

PDF (PC)

Knowledge

Cited

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments